The CARs consist of an anti-CD19 single-chain variable fragmentscFv that was derived from the FMC63 mouse hybridoma, a portion of the human CD1374-1BB molecule, and the intracellular component of the human CD3 molecule. Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.
The Main research objectives:
To evaluate the safety and efficacy of SL1904B in patients with recurrent or refractory non-Hodgkin's lymphoma
The Secondary research objectives:
To investigate the cytokinetic characteristics of SL1904B in patients with recurrent or refractory non-Hodgkin's lymphoma.
How understandable was the trial content above?
Hard to understand
Easy to understand
